The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.

The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.

The present invention describes novel 7-alkylamino-3-(thienyl) coumarin fluorescent dyes of formula (I) ##STR00001## These dyes are water soluble, can be excited by the 405 nm excitation source and exhibit a large Stokes shift (80 nm). Furthermore, the dyes possess a reactive group for the labeling of biomolecules or other analytes.

The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

The present invention relates to single domain antibodies (SDAs) that are capable of binding to tetanus neurotoxin. The invention further relates to polypeptide constructs comprising such an SDA as well as an SDA that is capable of binding to a serum protein, preferably to serum albumin or immunoglobulin. The invention also relates to nucleic acids encoding such SDAs or polypeptide constructs, to pharmaceutical compositions comprising such SDAs or polypeptide constructs, the medical use thereof and to their use in the treatment of tetanus.

This invention provides, and in certain specific but non-limiting aspects relates to:assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal;methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal;modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal;ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal;modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.

The present invention relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The invention further relates to the antigen-binding proteins that can be used in the method of the invention. The framework regions of the antigen-binding proteins of the invention preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The invention further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species.

The instant disclosure provides antibody fragments (e.g., Fab and F(ab).sub.2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.

IgG epitope and applications thereof as a target are provided. The IgG epitope is the C.sub.H1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.